The success of clinically relevant immunotherapies requires reversing tumor-induced immunosuppression. Here we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulatory DCs expressing CD11c and programmed cell death 1–ligand 1 (PD-L1) at ovarian cancer locations in mice. PEI-siRNA uptake transformed these DCs from immunosuppressive cells to efficient antigen-presenting cells that activated tumor-reactive lymphocytes and exerted direct tumoricidal activity, both in vivo and in situ. PEI triggered robust and selective TLR5 activation in vitro and elicited the production of hallmark TLR5-inducible cytokines in WT mice, but not in Tlr5–/– littermates. Thus, PEI is a TLR5 agonist that, to our knowledge, was not previously recognized. In addition, PEI-complexed nontargeting siRNA oligonucleotides stimulated TLR3 and TLR7. The nonspecific activation of multiple TLRs (specifically, TLR5 and TLR7) reversed the tolerogenic phenotype of human and mouse ovarian tumor–associated DCs. In ovarian carcinoma–bearing mice, this induced T cell–mediated tumor regression and prolonged survival in a manner dependent upon myeloid differentiation primary response gene 88 (MyD88; i.e., independent of TLR3). Furthermore, gene-specific siRNA-PEI nanocomplexes that silenced immunosuppressive molecules on mouse tumor-associated DCs elicited discernibly superior antitumor immunity and enhanced therapeutic effects compared with nontargeting siRNA-PEI nanocomplexes. Our results demonstrate that the intrinsic TLR5 and TLR7 stimulation of siRNA-PEI nanoparticles synergizes with the gene-specific silencing activity of siRNA to transform tumor-infiltrating regulatory DCs into DCs capable of promoting therapeutic antitumor immunity.
Juan R. Cubillos-Ruiz, Xavier Engle, Uciane K. Scarlett, Diana Martinez, Amorette Barber, Raul Elgueta, Li Wang, Yolanda Nesbeth, Yvon Durant, Andrew T. Gewirtz, Charles L. Sentman, Ross Kedl, Jose R. Conejo-Garcia
Title and authors | Publication | Year |
---|---|---|
mRNA Vaccine Nanoplatforms and Innate Immunity.
Wei L, Dong C, Zhu W, Wang BZ |
Viruses | 2024 |
Sulfonium‐Stapled Peptides‐Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention
Zhang Y, Jiang L, Huang S, Lian C, Liang H, Xing Y, Liu J, Tian X, Liu Z, Wang R, An Y, Lu F, Pan Y, Han W, Li Z, Yin F |
Advanced Science | 2024 |
Identification of potential immune-related mechanisms related to the development of multiple myeloma
Wang Y, Zhang W, Li T, Liu M, Gao M, Li X, Chen Y, Song Y, Li W, Du C, Wang F, Liu L |
Chinese Medical Journal | 2024 |
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential
Binder AK, Bremm F, Dörrie J, Schaft N |
International journal of molecular sciences | 2024 |
Nanotechnology for boosting ovarian cancer immunotherapy.
Kaur P, Singh SK, Mishra MK, Singh S, Singh R |
Journal of ovarian research | 2024 |
Transgelin 2 guards T cell lipid metabolism and antitumour function.
Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Marin Falco M, Salvagno C, Emmanuelli A, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Yu X, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR |
Nature | 2024 |
New insights for the development of efficient DNA vaccines
Berger S, Zeyn Y, Wagner E, Bros M |
Microbial Biotechnology | 2024 |